Navigation Links
Levosimendan improves event free survival by 50 percent in end-stage heart failure
Date:5/27/2013

Lisbon, 27 May 2013: Ambulatory levosimendan improves event free survival by 50% compared to placebo, according to results from the LevoRep Study presented today during the late breaking trial session1 of the Heart Failure Congress 2013. In a second study, the third generation mineralocorticoid receptor antagonist (MRA) BAY 94-8862 showed improved potassium and kidney tolerance in heart failure patients with chronic kidney disease (CKD).

Heart Failure 2013 is the main annual meeting of the Heart Failure Association of the European Society of Cardiology and is being held 25-28 May in Lisbon, Portugal (1)

The prevalence of end-stage heart failure is increasing significantly and is associated with frequent hospital admissions and high costs. LevoRep is the largest trial of repetitive ambulatory administration of an inotrope in end-stage heart failure. The study focused on the safety and efficacy of levosimendan in an ambulatory setting.

LevoRep was a multicentre study in which 120 patients with end-stage heart failure were randomised to receive biweekly 0.2 mcg/kg/min levosimendan for 6 hours over 6 weeks or placebo. The study met its secondary endpoints and showed that ambulatory levosimendan was safe and improved event free survival by 50% compared with placebo. However, the study failed to show significant improvements in functional capacity and quality of life which were the primary endpoints.

Presenter Dr Gerhard Poelzl (Austria) said: "Future studies with more patients and higher dosing or higher repetition frequencies of levosimendan in an outpatient setting could show positive results for the primary endpoints. The improvement in event-free survival shown in this study may revive an old concept of ambulatory treatment of end-stage heart failure patients which has been largely dismissed because of the excessive mortality with intropes."

The MinerAlocorticoid Receptor Antagonist Tolerability Study (ARTS) was a randomised, double blind, phase 2 trial of BAY 94-8862 in patients with chronic heart failure and mild/moderate chronic kidney disease. First (spironolactone) and second (eplerenone) generation MRAs have safety issues including risk of hyperkalemia and worsened renal function. Their use is limited in patients with poor renal function, a frequent comorbidity in patients with heart failure.

The fourth generation MRA BAY 94-8862 is non-steroidal and BAY 94-8862 is thought to be more kidney friendly. This is due to its pharmacokinetics of distribution where the drug tends to be compartmentalised to a greater extent in the heart than the kidneys when compared to spironolactone and eplerenone in rodents, suggesting targeted action on the cardiovascular system with fewer effects on the kidney.

Part B of the ARTS trial, presented today, randomised 393 patients with heart failure and moderate CKD to BAY 94-8862 (2.5, 5, or 10mg once daily or 5mg twice daily), placebo or the standard dose of spironolactone.

All BAY 94-8862 doses were safe and well tolerated and BAY 94-8862 was associated with less hyperkalemia and better kidney tolerance than spironolactone. Both drugs produced an almost equal effect on brain natriuretic peptide (BNP), a hemodynamic biomarker of remodelling of the heart.

Presenter Professor Faiez Zannad (France) said: "This fourth generation drug is better tolerated when it comes to potassium and the kidney even in patients at higher risk because of pre-existing moderate CKD. There is a real unmet need in this population because while MRAs are not contraindicated, many doctors are wary of using them because of the side effects in the kidney. This study is the first important step towards investigating newer and wider indications for MRAs."

He concluded: "Future studies will investigate BAY 94-8862 novel indications: patients with heart failure and either moderate CKD or diabetes hospitalized for worsening chronic heart failure, and kidney protection in diabetics."


'/>"/>

Contact: Jacqueline Partarrieu
press@escardio.org
33-492-947-756
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Clinical insight improves treatment with new lung cancer drug
2. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
3. Exercise improves quality of life during breast cancer treatment
4. Early treatment improves outcomes in rare, often undiagnosed form of encephalitis
5. NYUCNs Dr. Laura Wagner: Study finds accreditation improves safety culture at nursing homes
6. Brief training program improves resident physicians empathy with patients
7. A nurse practitioner-driven palliative care intervention improves cancer patients quality of life
8. Oxytocin improves brain function in children with autism
9. Nordic walking improves health of heart failure patients
10. Donor aortic graft improves reconstruction after partial laryngectomy
11. Vitamin C improves pulmonary function in newborns of pregnant smoking women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... York, NY (PRWEB) , ... May 25, 2016 ... ... Medicine and Florida International University (FIU) Herbert Wertheim College of Medicine announced the ... a Medical Doctor Degree and Global Health Certificate from AUA and a Certificate ...
(Date:5/25/2016)... , ... May 25, 2016 , ... Dr. Travis Schwarz ... Plaza at 8618 Mexico Road, O’Fallon, MO 63366. He serves patients of all ages ... cosmetic treatments . Dr. Schwarz’s success is reflected in the superior patient reviews that ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... Today Omega ... launch of 11 innovative workshops and training opportunities in the growing field ... unique needs of individuals who are dealing with specific health issues—including injuries, illnesses, and ...
(Date:5/25/2016)... ... May 25, 2016 , ... Cheryl Bowker of Bowker Insurance Group ... Dick McKenna Good Hands Legacy Award. McKenna ran one of Allstate’s most successful agencies ... inspire all those who knew him. The award named for him is not given ...
(Date:5/25/2016)... ... 2016 , ... The Global Wellness Summit (GWS) today announced that its 2016 ... Europe, a continent that pioneered the medical/wellness concept for the world. , Delegates to ... wellness, including Henri Chenot, Founder of the Chenot Group, which operates wellness centers around ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016   , Study ... overall bowel cleansing and superiority in , ... of the ascending colon ... Norgine B.V. today announced new positive data from the ... bowel preparation) versus standard 2 litre PEG with ascorbate. The study ...
(Date:5/24/2016)... N.J. , May 24, 2016 ... oncology drug development company, today provided an update ... dose escalating clinical trial combining GEN-1, the Company,s ... the treatment of newly-diagnosed patients with advanced ovarian ... interval debulking surgery.  GEN-1 is an IL-12 DNA ...
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse ... cathéters destinés à l,intervention portant sur les ...   OrbusNeich, entreprise mondiale spécialisée ... de changer la vie, a élargi son ...
Breaking Medicine Technology: